Objective-To test the hypothesis that the addition of nitrates improves exercise tolerance in patients with heart failure caused by coronary artery disease already treated with an angiotensin converting' enzyme inhibitor and diuretics. Design-Randomised, double blind, placebo controlied, 16 week treatment periods. Setting-Outpatient clinic at a university hospital. Patients-54 patients with previous myocardial infarction, symptoms of mild to moderate heart failure, left ventricular ejection fraction below 40 %, no exerciseinduced angina or electrocardiographic signs of ischaemia. Four patients in the nitrate group (n = 24) and one patient of the placebo group (n = 25) were withdrawn from the study.
verting' enzyme inhibitor and diuretics. Design-Randomised, double blind, placebo controlied, 16 week treatment periods. Setting-Outpatient clinic at a university hospital. Patients-54 patients with previous myocardial infarction, symptoms of mild to moderate heart failure, left ventricular ejection fraction below 40 %, no exerciseinduced angina or electrocardiographic signs of ischaemia. Four patients in the nitrate group (n = 24) and one patient of the placebo group (n = 25) were withdrawn from the study. Intervention-After the patients had been on constant doses of captopril and diuretics for at least 2 weeks, they were randomised to receive a target dose of 40 mg isosorbide dinitrate twice daily or placebo in addition to the continuation of captopril and diuretics. Measurements-Bicycle exercise tests with measurement of gas exchange were carried out before randomisation and after 1, 6, 12, and 16 weeks of the double blind treatment. The change in peak oxygen uptake from control to week 16 was prospectively defined as the main outcome measure.
Results-The increase in peak oxygen uptake from before randomisation tended to be greater in the placebo group (before randomisation 17-4 (3.4) mllminl kg) than in the nitrate group (before randomisation 17-1 (3.5) mllminlkg) after 12 weeks (mean increase 1 1 (2.7) v 0 0 (2.7) mllminlkg, p < 0.12) and 16 weeks (17 (3.0) v 0 3 (2.6) mllminlkg, p < 0.14) of treatment.
Conclusion-The addition of nitrates to a baseline treatment consisting of captopril and diuretics did not improve exercise tolerance.
(Br Heart J 1993;70: [17] [18] [19] [20] [21] Angiotensin converting enzyme inhibitors are now widely used for the treatment of chronic congestive heart failure, mostly in combination with diuretics.' The long-term efficacy of nitrates in congestive heart failure has been a matter of controversy2 I but some studies suggested that nitrates given either as the sole vasodilator or in combination with other vasodilators are useful in this condition. Laboratory tests including blood chemistry and blood cell count were carried out at entry; before randomisation; and at weeks 1, 6, and 16 on randomised medication.
EXERCISE TESTING WITH MEASUREMENT OF RESPIRATORY GAS EXCHANGE
Semisupine bicycle exercise with breath-bybreath analysis of gas exchange was carried out on an electronically braked cycle ergometer (Ergo-metrics 900, Ergoline, Bitz, Germany). The workload was increased at a rate of 10 W per minute according to a ramp protocol until the symptom-limited maximum was reached. The patients were encouraged to exercise to an all-out effort before the stress test was begun. They were not pushed to exercise harder during the stress test. All exercise tests were stopped at the patient's request. Gas exchange was measured with an ergospirometry system (MCG Systems 2001, Medical Graphics, St Paul, USA).
The slope of the relation between oxygen uptake (ordinate) and workload (abscissa) was determined for each study by linear regression analysis. The initial 20 W were excluded from the analysis because of the kinetic lag in oxygen uptake after the onset of incremental work.'2 This slope was proposed as a measure of the ability of the circulatory system to deliver oxygen to the working muscle and is referred to as oxygen uptake kinetics in this paper."3 The total ventilatory response to exercise, defined as the slope of the relation between minute ventilation (ordinate) and carbon dioxide production (abscissa), was also determined. ' (17) graphy before the study. For the remaining two patients we had radionuclide ejection fraction data. Twenty four patients were randomised to receive nitrates and 25 to receive placebo. The two groups were similar at entry for demographic and functional variables, concomitant medications, and pre-treatment with converting enzyme inhibitors and nitrates (see table) . Four patients of the nitrate-group and one patient of the placebo group were withdrawn. The reasons for withdrawal in the nitrate-group were angina of new onset in one (week 1), sustained ventricular tachycardia in two (weeks 1 and 6) and headache in one (week 2). The patient of the placebo group was excluded because of noncompliance (week 6). The study drug had to be reduced to half doses within the first 2 weeks after randomisation in two patients in the nitrate group because of headache. FUNCTIONAL (fig 1) . There was no difference in the changes in resting blood pressure and body weight since randomisation between the two groups.
EXERCISE TOLERANCE AND RESPIRATORY GAS EXCHANGE
The groups did not differ at pre-randomisation examination with respect to peak oxygen uptake, oxygen uptake kinetics, and total ventilatory response to exercise. The increase in peak oxygen uptake tended to be greater in the placebo group than in the nitrate group after 12 weeks (mean increase from control: l-(2-7) v 0 0 (2 7) ml/min/kg, p < 0 12) and 16 weeks (1.7 (3-0) v 0-3 (2 6) ml/min/kg, p < 0d14) of randomised treatment. Figure 2 shows the time course of peak oxygen uptake. The changes in oxygen uptake kinetics and total ventilatory response to exercise were negligible in both groups.
LABORATORY STUDIES
The changes in blood chemistry were unremarkable. Specifically, combination therapy with captopril and isosorbide dinitrate had no adverse effect on renal function.
Discussion
The finding that the increase in exercise tolerance tended to be greater in the placebo group than in the nitrate group after 12 weeks and 16 weeks of treatment was unexpected. The trend in favour of placebo was noted whether the data were analysed according to the intent-to-treat principle or by evaluating only those patients who completed the 16 weeks of randomised treatment (week 12, p < 0-22; week 16, p < 028).
The principal therapeutic goal in congestive heart failure is to improve survival. The effect of an intervention on exercise tolerance is only a surrogate endpoint. Recent Figure 2 Peak oxygen uptake in the placebo group and in the nitrate group during the course of the study. 12 16
that mortality was reduced more by a combination of isosorbide dinitrate and hydralazine than by placebo. It is not clear which of the two agents, isosorbide dinitrate or hydralazine or a specific drug interaction, caused the improvement of prognosis. Whether the addition of nitrates to a converting enzyme inhibitor confers long-term prognostic benefit is also unclear. A large trial of several thousands of patients followed for a few years would be required to answer this question. Cohn2 has pointed out that economic factors make such a trial unlikely. Many pharmaceutical companies produce nitrate preparations and it is unlikely that a single company would fund a large mortality trial because even a positive outcome would not increase their market share and profit to meet the high costs of such a study. Combination therapy with captopril and nitrates has theoretical appeal so why did nitrates in this study not improve exercise tolerance? A nitrate-induced reflex activation of the sympathoadrenal axis or of the reninangiotensin system cannot explain the lack of effect of nitrates because intermittent treatment with nitrates does not activate these counterregulatory forces.'7 Also the reninangiotensin system was blocked by captopril. Nitrates produced a slight increase in resting heart rate. It is interesting to speculate that nitrates reduced the antisympathetic cardiac effects of captopril, which might be one of the mechanisms by which converting-enzyme inhibitors counteract left ventricular remodelling. Capewell 32 suggested the combined use of a converting enzyme inhibitor and a different type of vasodilator to obtain maximum benefit in terms of survival and exercise tolerance. We found no evidence that the addition of nitrates to captopril improved exercise tolerance in coronary patients with mild to moderate heart failure and without evidence of ischaemia. Whether mortality is favourably affected when nitrates are added to a converting enzyme inhibitor is unclear. We therefore cannot recommend the use of nitrates as an adjunct to converting enzyme inhibitors. Less may be better than more in these patients.
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